MarketCapExport financials
Corbus Pharmaceuticals Holdings (CRBP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Corbus Pharmaceuticals Holdings Balance Sheet 2025-2011 | CRBP
Brief balance sheet overview of Corbus Pharmaceuticals Holdings
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets advanced +56.1% to $168.2 million from $107.7 million; annual growth near 11.8% reflects a fast increase in scale.
Assets outpaced liabilities, +56.1% versus -46.4%. Dependence on external funding declined.
Equity funds 87.7% of assets versus 64.1% initially. This creates a conservative balance sheet structure.
Cash accounts for 16.9% of assets versus 23.2% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$555.4 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Corbus Pharmaceuticals Holdings shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet Corbus Pharmaceuticals Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -14 M | - | 263 K | -8.23 M | -66.7 M | -22.3 M | -41.4 M | -62.2 M | -14.7 M | -12.2 M | -6.12 M | 335 K | - | - |
Long Term Debt |
- | 1.63 M | - | 16 M | 15.6 M | 18 M | - | - | - | - | - | - | 331 K | - | - |
Long Term Debt Current |
1.63 M | 1.61 M | 1.44 M | 1.28 M | 1.14 M | 1 M | 596 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 25.1 M | 8.1 M | 1.38 M | 990 K | 70.4 K | 260 K | - | 1.44 M | - | - |
Total Current Liabilities |
20.7 M | 11.8 M | 31.9 M | 12.6 M | 17 M | 31.9 M | 34.9 M | 18.1 M | 8.2 M | 8.9 M | 3.63 M | 738 K | - | - | - |
Total Liabilities |
20.7 M | 13.5 M | 35.2 M | 33.3 M | 38.6 M | 57 M | 43 M | 19.5 M | 9.19 M | 8.97 M | 3.89 M | 738 K | 2.09 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 1.46 M | - | 1.94 M | 1.59 M | - | - | - | - |
Retained Earnings |
-555 M | -477 M | -437 M | -392 M | -350 M | -304 M | -193 M | -121 M | -65.7 M | -33.3 M | -13.3 M | -4.43 M | -1.89 M | - | - |
Total Assets |
168 M | 156 M | 28.3 M | 66.3 M | 108 M | 102 M | 49.1 M | 47 M | 67 M | 17.9 M | 12.9 M | 6.6 M | 306 K | - | - |
Cash and Cash Equivalents |
28.5 M | 17.2 M | 13.7 M | 17 M | 25 M | 85.4 M | 31.7 M | 41.7 M | 62.5 M | 15 M | 12.3 M | 6.26 M | 303 K | - | - |
Book Value |
148 M | 142 M | -6.9 M | 33 M | 69.1 M | 45.3 M | 6.16 M | 27.5 M | 57.8 M | 8.92 M | 8.99 M | 5.86 M | -1.78 M | - | - |
Total Shareholders Equity |
148 M | 142 M | -6.9 M | 33 M | 69.1 M | 45.3 M | 6.16 M | 27.5 M | 57.8 M | 8.92 M | 8.99 M | 5.86 M | -1.78 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Corbus Pharmaceuticals Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.26 M | - | 307 K | 761 K | 1.2 M | 1.63 M | 2.05 M | 2.46 M | - | 3.24 M | - | 11.3 M | 14 M | 16 M | 9.39 M | 11.6 M | 13.7 M | 15.6 M | 18.6 M | 18.4 M | 18.2 M | 18 M | 18 M | 18 M | 18 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 1.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
24.7 M | 18.1 M | 17.4 M | 14.1 M | 12.8 M | 13.5 M | 13.7 M | 26.4 M | 28.8 M | 35.2 M | 36 M | 34.2 M | 35.2 M | 33.3 M | 31.9 M | 32.6 M | 34.5 M | 38.6 M | 41.9 M | 43.6 M | 48.6 M | 57 M | 57 M | 57 M | 57 M | 43 M | 43 M | 43 M | 43 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 9.19 M | 9.19 M | 9.19 M | 9.19 M | 8.97 M | 8.97 M | 8.97 M | 8.97 M | 3.89 M | 3.89 M | 3.89 M | 3.89 M | 738 K | 738 K | 594 K | 738 K | 980 K | 980 K | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 271 K | - | - | - | 2.48 M | 27 M | 1.46 M | 1.46 M | 4.48 M | 1.46 M | - | - | 296 K | 646 K | 1.94 M | 1.94 M | 1.94 M | 1.94 M | 1.59 M | 1.59 M | 1.59 M | 1.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-613 M | -578 M | -535 M | -512 M | -494 M | -477 M | -467 M | -454 M | -444 M | -437 M | -429 M | -419 M | -410 M | -392 M | -381 M | -372 M | -359 M | -350 M | -339 M | -337 M | -320 M | -304 M | -304 M | -304 M | -304 M | -193 M | -193 M | -193 M | -193 M | -121 M | -121 M | -121 M | -121 M | -65.7 M | -65.7 M | -65.7 M | -65.7 M | -33.3 M | -33.3 M | -33.3 M | -33.3 M | -13.3 M | -13.3 M | -13.3 M | -13.3 M | -4.43 M | -4.43 M | -4.43 M | -4.43 M | -1.89 M | -1.89 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
127 M | 144 M | 110 M | 125 M | 140 M | 156 M | 164 M | 152 M | 126 M | 28.3 M | 36.3 M | 43.7 M | 51.6 M | 66.3 M | 73.8 M | 82.1 M | 95.7 M | 108 M | 120 M | 121 M | 140 M | 102 M | 102 M | 102 M | 102 M | 49.1 M | 49.1 M | 49.1 M | 49.1 M | 47 M | 47 M | 47 M | 47 M | 67 M | 67 M | 67 M | 67 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 306 K | 306 K | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
23.4 M | 25.7 M | 27 M | 20 M | 18.9 M | 17.2 M | 19.4 M | 23.7 M | 14.1 M | 13.7 M | 11.2 M | 8.35 M | 7.32 M | 17 M | 12.4 M | 25.8 M | 57 M | 25 M | 37.1 M | 36.1 M | 66.6 M | 85.4 M | 85.4 M | 85.4 M | 85.4 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 41.7 M | 41.7 M | 41.7 M | 41.7 M | 62.5 M | 62.5 M | 62.5 M | 62.5 M | 15 M | 15 M | 15 M | 15 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 6.26 M | 6.26 M | 6.26 M | 6.26 M | 303 K | 303 K | - | - | 542 K | - | - | - | - | - | - | - |
Book Value |
102 M | 126 M | 92.1 M | 111 M | 127 M | 142 M | 150 M | 126 M | 97 M | -6.9 M | 311 K | 9.52 M | 16.5 M | 33 M | 41.9 M | 49.5 M | 61.2 M | 69.1 M | 77.6 M | 77 M | 91.5 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 6.16 M | 6.16 M | 6.16 M | 6.16 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 8.92 M | 8.92 M | 8.92 M | 8.92 M | 8.99 M | 8.99 M | 8.99 M | 8.99 M | 5.86 M | 5.86 M | 6.01 M | 5.86 M | -675 K | -675 K | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
102 M | 126 M | 92.1 M | 111 M | 127 M | 142 M | 150 M | 126 M | 97 M | -6.9 M | 312 K | 9.52 M | 16.5 M | 33 M | 41.9 M | 49.5 M | 61.2 M | 69.1 M | 77.6 M | 77 M | 91.5 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 6.16 M | 6.16 M | 6.16 M | 6.16 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 8.92 M | 8.92 M | 8.92 M | 8.92 M | 8.99 M | 8.99 M | 8.99 M | 8.99 M | 5.86 M | 5.86 M | 5.86 M | 5.86 M | -1.78 M | -1.78 M | - | - | -1.19 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Corbus Pharmaceuticals Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Schweiz
Canada
France
Australia
China
Israel
Germany
Britain
